Cancer‐generated lactic acid: a regulatory, immunosuppressive metabolite?

Abstract

The common preference of cancers for lactic acid‐generating metabolic energy pathways has led to proposals that their reprogrammed metabolism confers growth advantages such as decreased susceptibility to hypoxic stress. Recent observations, however, suggest that it generates a novel way for cancer survival. There is increasing evidence that cancers can escape immune destruction by suppressing the anti‐cancer immune response through maintaining a relatively low pH in their micro‐environment. Tumours achieve this by regulating lactic acid secretion via modification of glucose/glutamine metabolisms. We propose that the maintenance by cancers of a relatively low pH in their micro‐environment, via regulation of their lactic acid secretion through selective modification of their energy metabolism, is another major mechanism by which cancers can suppress the anti‐cancer immune response. Cancer‐generated lactic acid could thus be viewed as a critical, immunosuppressive metabolite in the tumour micro-environment rather than a ‘waste product’. This paradigm shift can have major impact on therapeutic strategy development. Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 53

1. 1.

   Warburg O. On respiratory impairment in cancer cells. Science. 1956;124::269-270.

   Not in our library

2. 2.

   Feron O. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol. 2009;92::329-333.

   Not in our library10.1016/j.radonc.2009.06.025

3. 3.

   Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008;134::703-707.

   Not in our library10.1016/j.cell.2008.08.021

4. 4.

   Shaw RJ. Glucose metabolism and cancer. Curr Opin Cell Biol. 2006;18::598-608.

   Not in our library10.1016/j.ceb.2006.10.005

5. 5.

   Jadvar H, Alavi A, Gambhir SS. 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med. 2009;50::1820-1827.

   Not in our library10.2967/jnumed.108.054098

6. 6.

   DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene. 2010;29::313-324.

   Not in our library10.1038/onc.2009.358

7. 7.

   Deberardinis RJ, Sayed N, Ditsworth D, et al. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev. 2008;18::54-61.

   Not in our library10.1016/j.gde.2008.02.003

8. 8.

   Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144::646-674.

   Not in our library10.1016/j.cell.2011.02.013

9. 9.

   Daye D, Wellen KE. Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. Semin Cell Dev Biol. 2012;23::362-369.

   Not in our library10.1016/j.semcdb.2012.02.002

10. 10.

    Webb BA, Chimenti M, Jacobson MP, et al. Dysregulated pH: a perfect storm for cancer progression. Nature Rev Cancer. 2011;11::671-677.

    Not in our library10.1038/nrc3110

11. 11.

    Calcinotto A, Filipazzi P, Grioni M, et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res. 2012;72::2746-2756.

    Not in our library10.1158/0008-5472.can-11-1272

12. 12.

    De Milito A, Canese R, Marino ML, et al. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer. 2010;127::207-219.

    Not in our library10.1002/ijc.25009

13. 13.

    Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nature Rev Cancer. 2004;4::891-899.

    Not in our library10.1038/nrc1478

14. 14.

    Warburg O. On the origin of cancer cells. Science. 1956;123::309-314.

    Not in our library10.1126/science.123.3191.309

15. 15.

    Chandra D, Singh KK. Genetic insights into OXPHOS defect and its role in cancer. Biochim Biophys Acta. 2011;1807:620-625.

    Not in our library10.1016/j.bbabio.2010.10.023

16. 16.

    Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006;9::425-434.

    Not in our library10.1016/j.ccr.2006.04.023

17. 17.

    Kimura H, Braun RD, Ong ET, et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res. 1996;56::5522-5528.

    Not in our library

18. 18.

    Draoui N, Feron O. Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments. Dis Model Mech. 2011;4::727-732.

    Not in our library10.1242/dmm.007724

19. 19.

    Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324::1029-1033.

    Not in our library10.1126/science.1160809

20. 20.

    Zu XL, Guppy M. Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun. 2004;313::459-465.

    Not in our library10.1016/j.bbrc.2003.11.136

21. 21.

    Harjes U, Bensaad K, Harris AL. Endothelial cell metabolism and implications for cancer therapy. Br J Cancer. 2012;107::1207-1212.

    Not in our library10.1038/bjc.2012.398

22. 22.

    Polet F, Feron O. Endothelial cell metabolism and tumour angiogenesis: glucose and glutamine as essential fuels and lactate as the driving force. J Intern Med. 2013;273::156-165.

    Not in our library10.1111/joim.12016

23. 23.

    Hamaï A, Benlalam H, Meslin F, et al. Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune? Tissue Antigens. 2010;75::1-8.

    Not in our library10.1111/j.1399-0039.2009.01401.x

24. 24.

    Lardner A. The effects of extracellular pH on immune function. J Leukoc Biol. 2001;69::522-530.

    Not in our library

25. 25.

    Kellum JA. Metabolic acidosis in patients with sepsis: epiphenomenon or part of the pathophysiology? Crit Care Resusc. 2004;6::197-203.

    Not in our library

26. 26.

    Kellum JA, Song M, Li J. Lactic and hydrochloric acids induce different patterns of inflammatory response in LPS-stimulated RAW 264.7 cells. Am J Physiol Regul Integr Comp Physiol. 2004;286::R686-R692.

    Not in our library10.1152/ajpregu.00564.2003

27. 27.

    Gottfried E, Kunz-Schughart LA, Ebner S, et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood. 2006;107::2013-2021.

    Not in our library10.1182/blood-2005-05-1795

28. 28.

    Fischer K, Hoffmann P, Voelkl S, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007;109::3812-3819.

    Not in our library10.1182/blood-2006-07-035972

29. 29.

    Goetze K, Walenta S, Ksiazkiewicz M, et al. Lactate enhances motility of tumor cells and inhibits monocyte migration and cytokine release. Int J Oncol. 2011;39::453-463.

    Not in our library10.3892/ijo.2011.1055

30. 30.

    Mendler AN, Hu B, Prinz PU, et al. Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c-Jun activation. Int J Cancer. 2012;131::633-640.

    Not in our library10.1002/ijc.26410

31. 31.

    Ohashi T, Akazawa T, Aoki M, et al. Dichloroacetate improves immune dysfunction caused by tumor-secreted lactic acid and increases antitumor immunoreactivity. Int J Cancer.

    Not in our library10.1002/ijc.28114

32. 32.

    Mazzio EA, Boukli N, Rivera N, et al. Pericellular pH homeostasis is a primary function of the Warburg effect: inversion of metabolic systems to control lactate steady state in tumor cells. Cancer Sci. 2012;103::422-432.

    Not in our library10.1111/j.1349-7006.2012.02206.x

33. 33.

    Sola-Penna M. Metabolic regulation by lactate. IUBMB Life. 2008;60::605-608.

    Not in our library10.1002/iub.97

34. 34.

    Hirschhaeuser F, Sattler UG, Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res. 2011;71::6921-6925.

    Not in our library10.1158/0008-5472.can-11-1457

35. 35.

    Yao F, Zhao T, Zhong C, et al. LDHA is necessary for the tumorigenicity of esophageal squamous cell carcinoma. Tumour Biol. 2013;34::25-31.

    Not in our library10.1007/s13277-012-0506-0

36. 36.

    Zhang Y, Zhang X, Wang X, et al. Inhibition of LDH-A by lentivirus-mediated small interfering RNA suppresses intestinal-type gastric cancer tumorigenicity through the downregulation of Oct4. Cancer Lett. 2012;321::45-54.

    Not in our library10.1016/j.canlet.2012.03.013

37. 37.

    Gallagher SM, Castorino JJ, Wang D, et al. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res. 2007;67::4182-4189.

    Not in our library10.1158/0008-5472.can-06-3184

38. 38.
    Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer · 2011

    No notice
39. 39.

    Choi SY, Gout PW, Collins CC, et al. Epithelial immune cell-like transition (EIT): a proposed transdifferentiation process underlying immune-suppressive activity of epithelial cancers. Differentiation. 2012;83::293-298.

    Not in our library10.1016/j.diff.2012.02.005

40. 40.

    Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. Mol Cell. 2012;48::158-167.

    Not in our library10.1016/j.molcel.2012.09.025

Cited by papers we hold 17

• Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy · 2024
  No notice
• The role of AMPK in cancer metabolism and its impact on the immunomodulation of the tumor microenvironment · 2023
  No notice
• Metabolic Reprogramming Induces Macrophage Polarization in the Tumor Microenvironment · 2022
  No notice
• Metabolic reprogramming in macrophage responses · 2021
  No notice
• Lactate Is a Metabolic Mediator That Shapes Immune Cell Fate and Function · 2021
  No notice
• Lactic Acid and an Acidic Tumor Microenvironment suppress Anticancer Immunity · 2020
  No notice
• Metabolism in tumor microenvironment: Implications for cancer immunotherapy · 2020
  No notice
• T Cell Dysfunction in Cancer Immunity and Immunotherapy · 2019
  No notice
• Stress-induced epinephrine enhances lactate dehydrogenase A and promotes breast cancer stem-like cells · 2019
  No notice
• Lactate and Immunosuppression in Sepsis · 2018
  No notice
• Systems analysis of intracellular pH vulnerabilities for cancer therapy · 2018
  No notice
• Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy · 2018
  No notice
• Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy · 2017
  No notice
• Lactate Contribution to the Tumor Microenvironment: Mechanisms, Effects on Immune Cells and Therapeutic Relevance · 2016
  No notice
• Antimicrobial and immune modulatory effects of lactic acid and short chain fatty acids produced by vaginal microbiota associated with eubiosis and bacterial vaginosis · 2015
  No notice
• Regulation of pyruvate metabolism and human disease · 2013
  No notice
• Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs – an integral molecular/biochemical/metabolic/clinical approach after one hundred years of cancer research · 2013
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.